Relay Therapeutics, Inc.
RLAY- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001812364
In the last 90 days, Relay Therapeutics, Inc. insiders filed 0 open-market purchases and 14 sales; 259 institutions reported holding it in 13F filings for Q2 2026, worth $4.58B in total; Duquesne Family Office is the only superinvestor holding it.
Superinvestors holding RLAY, Q2 2026
1 superinvestor reports holding Relay Therapeutics, Inc. on Form 13F, worth $6.53M in total. Weight is Relay Therapeutics, Inc.'s share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Duquesne Family OfficeStanley Druckenmiller | 0.1% | 349,000 | $6.53M | New |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of RLAY each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q2 2026
1 superinvestor holding at quarter end
Q4 2022
0 superinvestors holding at quarter end
- Sold out
- Third Point
Q3 2022
1 superinvestor holding at quarter end
- New
- Third Point